Table 3.
Exposure to treatment for patients treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)
| All (n = 62) | FOLFOX + Cmab (n = 37) | XELOX + Cmab (n = 25) | |
|---|---|---|---|
| No. treatment cycles | |||
| Median | 10 (5.5–17.5) | 10 (5–19) | 9.5 (6–14) |
| Cetuximab treatment | |||
| Cumulative dose (mg/m2) | 6480 (2187–12 480) | 6750 (3580–14 634) | 6397 (4302–11 198) |
| DI (mg/m2 per week) | 216 (189–247) | 223 (189–233) | 237 (179–261) |
| No. with relative DI >75 % | 52 | 28 | 24 |
| Oxaliplatin | |||
| Cumulative dose (mg/m2) | 992 (600–1812) | 987 (505–2021) | 1008 (661–1597) |
| DI (mg/m2 per week) | 31.4 (24–39) | 30 (28–35) | 39 (29–42) |
| No. with relative DI >75 % | 37 | 20 | 17 |
| Bolus 5-FU | |||
| Cumulative dose (mg/m2) | 4392 (1795–9928) | ||
| DI (mg/m2 per week) | 135 (120–175) | ||
| No. with relative DI >75 % | 21 | ||
| 5-FU Infusion | |||
| Cumulative dose (mg/m2) | 28414 (14750–60644) | ||
| DI (mg/m2 per week) | 890 (803–1062) | ||
| No. with relative DI >75 % | 21 | ||
| Capecitabine | |||
| Cumulative dose (mg/m2) | 23700 (14250–38925) | ||
| DI (mg/m2 per week) | 878 (666–978) | ||
| No. with relative DI >75 % | 16 |
Numbers in parenthesis show the interquartile range
DI dose intensity, 5-FU 5-fluorouraci